Status:
COMPLETED
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Hypertension
Left Ventricular Hypertrophy
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood p...
Eligibility Criteria
Inclusion
- Patients with essential hypertension
- Patients with a BMI \> 25 kg/m2
- Patients with LVH (LVWT ≥ 1.3 cm) confirmed by the ECHO
Exclusion
- Patients treated with an ACE or an ARB within 3 months of study entry (Study Visit 1) who are unable or unwilling to undergo the 3 month washout period.
- Patients treated with an ACE and ARB combination at study entry.
- Known secondary hypertension of any etiology (e.g., uncorrected renal artery stenosis).
- Other protocol related inclusion/exclusion criteria applied to the study.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT00219141
Start Date
October 1 2005
End Date
November 1 2007
Last Update
May 26 2011
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
sites in Argentina
Argentina, Argentina
3
sites in Colombia
Colombia, Colombia
4
sites in Finland
Finland, Finland